Recent Progress in Helicobacter pylori Treatment
Helicobacter pylori (H. pylori) is a Gram-negative, spiral-shaped, microaerophilic bacterium that colonizes the human stomach. It is a major causative agent of various gastric and extra-gastric diseases, including chronic gastritis, peptic ulcers, gastric mucosa-associated lymphoid tissue (MALT) lymphoma, gastric cancer, and iron deficiency anemia. Approximately half of the global population is infected with H. pylori, with prevalence rates varying significantly across regions due to differences in economic and social conditions. The global annual recurrence rate of H. pylori has increased from 3.9% in the 1990s to 4.8% in the 2010s, highlighting the need for effective eradication strategies.
The primary challenge in H. pylori treatment is the rising prevalence of antibiotic resistance, which significantly impacts the efficacy of eradication regimens. Resistance rates to commonly used antibiotics such as clarithromycin, metronidazole, and levofloxacin have exceeded 15% in all World Health Organization (WHO) regions, prompting the WHO to classify clarithromycin-resistant H. pylori as a high-priority bacterium in its list of antibiotic-resistant bacteria. Traditional proton-pump inhibitor (PPI)-based triple therapy, which combines a PPI with two antibiotics, has been the standard treatment for over two decades. However, its efficacy has declined, with intention-to-treat (ITT) eradication rates often falling below 80%, which is considered unacceptable. Consequently, alternative treatment strategies have been explored to improve eradication rates, particularly in regions with high antibiotic resistance.
Bismuth-containing quadruple therapy (BQT) has emerged as an effective first-line treatment for H. pylori eradication, especially in areas with high clarithromycin resistance. Bismuth, a non-antibiotic agent, has been used for centuries to treat various infections. When added to triple therapy, bismuth can improve eradication rates by 30-40% in resistant strains. A meta-analysis of 25 randomized trials involving 3,990 patients demonstrated that BQT achieved an eradication rate of 85.8%, significantly higher than the 74.2% observed with non-BQT regimens. In vitro studies have shown that bismuth reduces H. pylori’s ability to adhere to host cells, defend against oxidative stress, and buffer pH, which may explain its sustained antimicrobial activity and low resistance rates.
Several studies have evaluated the efficacy and safety of BQT in different populations. A prospective registry study in Europe involving 1,141 patients found that BQT achieved eradication rates of 88% (ITT) and 94% (per protocol, PP), with 14-day regimens outperforming 10-day regimens. Compliance was high, and no serious adverse reactions were reported. In Thailand, a once-daily dosing regimen of BQT achieved a 94% eradication rate, suggesting that tailored 14-day BQT could be an effective empiric therapy. In China, where bismuth is widely available, various BQT regimens have been recommended, with furazolidone-containing BQT showing high efficacy and safety. A study comparing furazolidone-based and clarithromycin-based BQT found no significant difference in eradication rates, but furazolidone-based therapy was more cost-effective. Half-dose clarithromycin-containing BQT also demonstrated similar efficacy to standard-dose therapy, with fewer adverse reactions and lower costs.
Sequential, hybrid, and concomitant therapies have also been explored as alternatives to traditional regimens. Sequential therapy, which involves a dual therapy phase followed by a triple therapy phase, was initially effective but has seen declining efficacy due to rising antibiotic resistance. Concomitant therapy, which combines three antibiotics with a PPI, has shown eradication rates above 90% in some studies, with comparable efficacy to BQT. Hybrid therapy, which combines elements of sequential and concomitant therapy, has also demonstrated high eradication rates, though its complexity may impact patient compliance. Reverse hybrid therapy, which involves PPI plus amoxicillin for 14 days and clarithromycin plus metronidazole for the initial 7 days, has shown similar efficacy to BQT, with fewer adverse events.
High-dose PPI-amoxicillin dual therapy (HDDT) has gained attention as a promising alternative that reduces the use of unnecessary antibiotics. HDDT involves high doses of amoxicillin and a PPI administered multiple times daily for 14 days. Studies have shown that HDDT achieves eradication rates comparable to BQT, with fewer side effects and lower costs. A randomized trial comparing modified HDDT to BQT found similar eradication rates, with HDDT showing better outcomes in patients with specific genetic variations. The addition of bismuth to HDDT did not significantly improve eradication rates, except in smokers. HDDT is particularly promising for elderly patients, who often experience adverse effects from multiple medications.
Vonoprazan (VPZ), a novel acid-inhibitory drug, has shown potential in improving H. pylori eradication rates. VPZ inhibits gastric acid more rapidly, strongly, and for a longer duration than traditional PPIs, and its efficacy is not influenced by CYP2C19 genotype. VPZ-based triple therapy has demonstrated superior efficacy compared to PPI-based triple therapy, particularly in clarithromycin-resistant strains. In Japan, the use of VPZ in first- and second-line eradication therapies has increased dramatically, leading to higher eradication rates. VPZ-based dual therapy has also shown similar efficacy to VPZ-based triple therapy, offering a simpler treatment option. The VONOSAP pack, which combines VPZ with other drugs in a blister pack, has improved drug adherence and eradication rates, particularly in elderly patients.
Susceptibility-guided therapy, which tailors treatment based on antibiotic resistance profiles, has been explored as a means to improve eradication rates and reduce antibiotic misuse. While theoretically effective, susceptibility-guided therapy has not consistently outperformed empiric therapy in clinical practice. The development of molecular tests, such as dual priming oligonucleotide-based multiplex polymerase chain reaction (DPO-PCR) and GenoType HelicoDR, has provided quick and convenient methods to guide tailored therapy. These tests have shown high efficacy and cost-effectiveness in regions with high antibiotic resistance.
Probiotics have been investigated as adjuncts to H. pylori eradication therapy, with specific strains showing potential to increase eradication rates and reduce adverse effects. Saccharomyces boulardii and Lactobacillus have been shown to improve the efficacy of triple therapy and reduce therapy-related diarrhea. Probiotics may also protect and restore the intestinal microbiota, which can be disrupted by H. pylori eradication. Vitamins, particularly vitamin C and E, have been shown to reduce oxidative stress and inhibit H. pylori activity. High-dose vitamin supplementation has been associated with increased eradication rates and reduced gastric cancer incidence. Vitamin D deficiency has been linked to higher H. pylori infection rates and lower eradication rates, suggesting a potential role for vitamin D supplementation in H. pylori management.
The search for novel anti-H. pylori compounds has identified several promising candidates. Chrysin and hesperetin have shown synergistic effects with clarithromycin and metronidazole, particularly in multidrug-resistant strains. Nitrobenzoxadiazole-based flavodoxin inhibitors have demonstrated low toxicity and high efficacy against resistant H. pylori strains in vitro and in vivo. These compounds represent potential new avenues for H. pylori treatment in the face of rising antibiotic resistance.
The establishment of H. pylori databases, such as the European Helicobacter and Microbiota Study Group’s registry, has provided valuable insights into the management of H. pylori infection. These databases allow researchers to track real-time information on treatment outcomes and conduct sub-analyses to identify effective strategies. The interim analysis of the European registry has confirmed the high efficacy and safety of BQT in routine clinical practice.
In conclusion, the treatment of H. pylori infection has evolved significantly in response to the challenges posed by antibiotic resistance. Bismuth-containing quadruple therapy remains a highly effective first-line treatment, while high-dose PPI-amoxicillin dual therapy and vonoprazan-based therapy offer promising alternatives. Susceptibility-guided therapy, probiotics, and vitamin supplementation have shown potential to improve eradication rates and reduce adverse effects. The development of novel anti-H. pylori compounds and the establishment of comprehensive databases will be crucial in advancing H. pylori management and reducing the global burden of H. pylori-related diseases.
doi.org/10.1097/CM9.0000000000000618
Was this helpful?
0 / 0